Idiopathic, hereditary, drug-induced, or anorexigen-induced PAH, or PAH associated with connective tissue disease;
Stable PAH treatment for at least 90 days;
Subjects capable of understanding the objectives and risks associated with the study and of providing dated and signed informed consent;
Subjects enrolled in a health insurance plan;
Subjects who have signed an informed consent form;
For women of childbearing age: negative pregnancy test at the screening/inclusion visit; effective contraception\* throughout the study (recommended in PAH)
* Effective and accepted methods of contraception during the study (subject, partner): oral contraceptive pill, intrauterine device (IUD), condom (male or female). Patients who practice total abstinence do not need to use contraception.
You may not be if
Patients treated with Omacor®;
Daily consumption of fish oil or fish oil-based dietary supplements (omega-3);
Hypersensitivity or allergy to fish, shellfish, peanuts, soy, corn oil, or coconut oil;
Anticoagulant therapy at therapeutic doses;
Cardiac decompensation within the month prior to enrollment;
Other causes of pulmonary hypertension (groups 2, 3, 4, or 5);
Persistent atrial fibrillation (AF);
Left ventricular ejection fraction \< 45% on echocardiography;
Recent episode of pulmonary embolism, within the past 6 months;
Myocardial infarction or placement of a coronary stent within the month prior to enrollment;
eGFR \< 30 mL/min/1.73 m²;
Malignant disease (not considered in remission);
Severe sepsis;
Participation in another clinical trial within the previous 3 months;
Subjects under legal guardianship, conservatorship, or curatorship
Clareo Health | Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
